Medical Condition News

RSS

$145M Federal Government effort to harness power of nanotechnology to improve cancer patients

A $145-million Federal Government effort to harness the power of nanotechnology to improve the diagnosis, treatment, and prevention of cancer is producing innovations that will radically improve care for the disease. That's the conclusion of an update on the status of the program, called the National Cancer Institute Alliance for Nanotechnology in Cancer.

29 Apr 2010

MU researcher develops test to pinpoint neurological origins of dysphagia

Muscle degeneration and confinement to a wheelchair are the hallmarks of Lou Gehrig's disease, Parkinson's, muscular dystrophy and other neurodegenerative diseases. One of the silent, and most serious, symptoms of these diseases is losing the ability to swallow.

29 Apr 2010

pSivida receives full payment of $15M note from Alimera Sciences

pSivida Corp., a leader in the development of ophthalmic sustained release drug delivery products, today said it had received full payment of a $15 million note, including an additional $225,000 in accrued interest, from Alimera Sciences, Inc., pSivida's licensee developing Iluvien® for the treatment of diabetic macular edema (DME).

29 Apr 2010

LCA acknowledges on-going work by ODP on lung cancer screening research

Lung Cancer Alliance acknowledges the on-going work by the Office of Disease Prevention at the National Institutes of Health on lung cancer screening research and the need for people who may be at risk for lung cancer to be well informed.

29 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis - a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

29 Apr 2010

Researchers examine how diagnosis of Fibromyalgia can affect marriages

Fibromyalgia is a condition that causes chronic, widespread pain throughout the body. In a new study, University of Missouri researchers are examining how the diagnosis of Fibromyalgia can affect marriages. Initial findings reveal that diagnosed spouses have considerably higher levels of depressive symptoms and pain and report more marital instability and anger than their spouses.

29 Apr 2010

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Pre-treatment with curcumin, a component of the spice turmeric, makes ovarian cancer cells more vulnerable to chemotherapy and radiotherapy. Researchers writing in BioMed Central's open access Journal of Ovarian Research found that delivering the curcumin via very small (less than 100nm) nanoparticles enhanced the sensitizing effect.

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals, Ltd. today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

29 Apr 2010

Combination of antibiotics can cure Chlamydia-induced ReA: Study

Researchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Great American Asthma Challenge movement to change asthma care in the U.S.

Every day 10 people die from asthma. Most healthcare providers agree that these deaths are preventable. Patient education, access to care and a healthy lifestyle are proven methods that lead to less severe asthma symptoms, fewer hospitalizations and emergency department visits, fewer missed days of school and work - and fewer deaths.

29 Apr 2010

Healthy food programs in grocery stores may help reduce diet-related illnesses

Bringing healthy food programs to corner grocery stores in the inner city might be a step toward improving residents' diet and reducing diet-related illnesses, a new study suggests.

29 Apr 2010

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Targeted Genetics Corporation announced today that its licensing partner, Celladon Corporation, has reported today that Celladon's first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

29 Apr 2010

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Hypertrophic Cardiomyopathy (HCM), the genetic disease in which the muscle of the heart thickens in the absence of an apparent cause, is the leading cause of sudden death in children and young adults. HCM accounts for 40 percent of all deaths on athletic playing fields across the U.S.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Medical Condition News

$145M Federal Government effort to harness power of nanotechnology to improve cancer patients

MU researcher develops test to pinpoint neurological origins of dysphagia

pSivida receives full payment of $15M note from Alimera Sciences

LCA acknowledges on-going work by ODP on lung cancer screening research

Fluorescent inhibitors hold promise for early-stage tumor detection

Multicenter NIH trial finds combination antibiotics effective against Chlamydia-induced reactive arthritis

Researchers examine how diagnosis of Fibromyalgia can affect marriages

Study: Curcumin nanoparticles limit toxicity of cancer therapy

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Study calls for optimized medical treatment for older patients with advanced lung cancer

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Combination of antibiotics can cure Chlamydia-induced ReA: Study

A new approach for treating neurological and degenerative disorders

Great American Asthma Challenge movement to change asthma care in the U.S.

Healthy food programs in grocery stores may help reduce diet-related illnesses

Celladon's first Phase II trial of MYDICAR for advanced heart failure meets primary endpoint

Renowned cardiologists to discuss latest research on Hypertrophic Cardiomyopathy at HCMA symposium

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Ceregene continues enrollment in new Phase 1/2 clinical study of CERE-120 for Parkinson's disease

Tumor cell factories may be difficult to defeat: Researchers

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News